Tevogen Bio Receives Nasdaq Delisting Notices for Market Value Non-Compliance

summarizeSummary

Tevogen Bio Holdings Inc. received notices from Nasdaq for failing to meet minimum market value requirements, initiating a 180-day period to regain compliance.

check_boxKey Events

• Nasdaq Non-Compliance Notification

  The company received letters from Nasdaq on April 16 and 17, 2026, for failing to meet the $50 million minimum market value for listed securities and the $15 million minimum market value of publicly held shares.

• 180-Day Compliance Period

  Tevogen Bio has 180 calendar days, until October 13 and October 14, 2026, respectively, to regain compliance by maintaining the required market values for at least 10 consecutive business days.

• Uncertainty of Regaining Compliance

  The company intends to monitor its market value and evaluate options, including a potential transfer to the Nasdaq Capital Market, but there is no assurance it will regain compliance or maintain its listing.

auto_awesomeAnalysis

Tevogen Bio Holdings Inc. has received two separate notices from Nasdaq regarding non-compliance with its continued listing requirements. The company failed to meet the minimum $50 million market value for listed securities and the $15 million minimum market value of publicly held shares. This is a critical development, especially given the company's precarious financial position, including a significantly increased net loss and a default on notes payable as reported in its last 10-K. While there is a 180-day period to regain compliance, the company's ability to do so is uncertain, and delisting could severely impact its access to capital and investor confidence. Investors should monitor the company's progress in addressing these deficiencies and its strategic options, including a potential transfer to the Nasdaq Capital Market.